Genetic Modifiers of Retinal Disease

视网膜疾病的基因修饰

• 批准号: 10574542
• 负责人: Patsy M Nishina
• 金额: $ 60.3万
• 依托单位: JACKSON LABORATORY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-03-01 至 2027-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10574542
• 关键词: Ablation; Address; Adult; Affect; Age of Onset; Alleles; Animal Model; Appearance; Atrophic; Automobile Driving; Biological; Blindness; CRISPR/Cas technology; Cells; Characteristics; Child; Clinical; Coats' disease; Cystoid Macular Edema; Development; Diagnosis; Disease; Enhancers; Environmental Exposure; Environmental Risk Factor; Family; Genes; Genetic; Genome; Genotype; Heritability; Human; Knock-out; Knowledge; Lead; Leber' s amaurosis; Leber' s disease; Mediating; Mendelian disorder; Microphthalmos; Modification; Molecular; Monoclonal Antibodies; Mus; Mutation; Onset of illness; Optic Disk Drusen; Pathogenicity; Pathologic; Pathology; Pathway Analysis; Pathway interactions; Patients; Pattern; Phenotype; Pigmentation physiologic function; Pigments; Population; Progressive Disease; Protein Isoforms; Public Health; Reporting; Resources; Retina; Retinal Detachment; Retinal Diseases; Retinitis Pigmentosa; Retinoschisis; Role; Severities; Severity of illness; Specificity; Telangiectasis; Testing; Therapeutic; Therapeutic Intervention; Tissues; Treatment outcome; Variant; Venous; arteriole; blind; cell type; cone-rod dystrophy; differential expression; disease phenotype; disease prognosis; early onset; effective therapy; gene augmentation therapy; improved; insight; macula; mouse model; mutant; personalized medicine; pre-clinical; precision medicine; preservation; prevent; response; segregation; targeted treatment; therapeutic evaluation; therapeutic target; treatment response

PROJECT SUMMARY/ABSTRACT Heritable retinal disorders, for which effective treatments are generally unavailable, contributes to the 1.02 million adults who are blind in the US. Among children, the heritable disease - Leber Congenital Amaurosis, accounts for 20% of blindness, and 10-15%of those are caused by mutations in the CRB1 gene. In addition to LCA, CRB1 mutations can also cause congenital or early-onset retinitis pigmentosa (RP), a more slowly progressive disease. CRB1 RP variants are sometimes associated with unique disease features, such as retinal telangiectasia with or without exudative retinal detachment (Coat's disease), a loss of RPE pigmentation except near arterioles (preservation of para-arteriolar RPE or PPRPE), pigment paravenous chorioretinal atrophy, cone-rod dystrophy, nanophthalmos with optic disc drusen, retinoschisis, cystoid macular edema, and macular dystrophic disease. The cause of the wide range of disease phenotypes associated with CRB1 mutations is not fully understood. Genotype-phenotype correlations that could explain the disease spectrum have not been detected among patients bearing CRB1 mutations, suggesting that environmental factors or genetic background modifiers contribute to the variability in the disease phenotypes observed. Another potential contributor to the phenotypic variability in disease presentation are Crb1 isoforms which have recently been shown to have spatially and temporally distinct expression patterns. Clearly, understanding the reasons for the variability and the mechanisms underlying the observed pathologies is extremely important for developing effective therapies. In this proposal, we will test the hypothesis that pathological changes due to Crb1 mutations depend upon the isoform affected and the genetic background on which it occurs, and their potential interactions. We will identify the molecular basis of genetic modifiers that enhance or suppress Crb1rd8 associated disease phenotypes or are epistatic upon Crb1rd8. Through the use of mouse models with isoform specific knockout alleles and controlled genetic backgrounds, we will determine their contribution to disease variability and the mechanisms through which they function. These studies address a critical unmet need for acquiring the basic biological knowledge necessary to develop effective therapies that can target the pre-symptomatic stage to prevent, delay onset or decrease severity of the disease. Animal models serve an important and unique role to further our understanding of the genetic underpinnings of disease and as a resource to examine tissue pathology, and to perform pre-clinical therapeutic tests that cannot be readily conducted in humans.

项目总结/摘要 遗传性视网膜疾病，有效的治疗通常是不可用的，有助于1.02 在美国，有100万成年人失明。在儿童中，遗传性疾病-莱伯先天性黑蒙， 占失明的20%，其中10- 15%是由CRB 1基因突变引起的。除了 LCA、CRB 1基因突变也可引起先天性或早发性视网膜色素变性（RP）， 进行性疾病CRB 1 RP变体有时与独特的疾病特征相关，例如 视网膜毛细血管扩张伴或不伴渗出性视网膜脱离（Coat病），RPE色素沉着丧失 除了小动脉附近（保留小动脉旁RPE或PPRPE），静脉旁脉络膜视网膜色素 萎缩、视锥-视杆营养不良、小眼球伴视盘玻璃疣、视网膜劈裂、黄斑囊样水肿，以及 黄斑营养不良性疾病与多种疾病表型相关的原因 CRB 1基因突变的研究还不完全清楚。可以解释该疾病的基因型-表型相关性 在携带CRB 1突变的患者中未检测到谱，这表明环境 遗传因素或遗传背景修饰因子有助于观察到的疾病表型的变异性。 疾病表现中表型变异性的另一个潜在贡献者是Crb 1同种型， 最近被证明具有空间和时间上不同的表达模式。显然，理解 变异性的原因和观察到的病理学的机制是非常重要的， 开发有效的治疗方法。 在这项提议中，我们将检验这样一个假设，即Crb 1突变引起的病理变化取决于 受影响的同种型及其发生的遗传背景，以及它们的潜在相互作用。我们将确定 增强或抑制Crb 1 rd 8相关疾病表型的遗传修饰剂的分子基础，或 在Crb 1 rd 8上上位。通过使用具有同种型特异性敲除等位基因的小鼠模型， 控制遗传背景，我们将确定它们对疾病变异性的贡献和机制， 通过它来运作。 这些研究解决了一个关键的未满足的需求，即获得发展所需的基本生物学知识， 针对症状前阶段的有效治疗，以预防、延迟发作或降低 这种疾病动物模型在进一步了解遗传学中起着重要而独特的作用。 疾病的基础，并作为检查组织病理学的资源，并进行临床前 在人体内无法轻易进行的治疗试验。